Sureda Anna, García-Sanz Ramón, Domingo-Domenech Eva, Capote Francisco Javier, Gutiérrez Antonio, Rodriguez Antonia, Aguiar David, Giraldo Pilar, Infante María Stefanía, López-Jiménez Javier, Martínez Carmen, Sánchez-González Blanca, Ortiz-Romero Pablo L, Grande Marta, Baeza-Montañez Lourdes
Intitut Català d'Oncologia, Duran i Reynals Hospital, IDIBELL, 08908 Hospitalet de Llobregat, Spain.
CIBERONC, Institute of Cancer and Hematological Diseases, Gregorio Marañón General University Hospital, FiBGM, Dr. Esquerdo 46, 28007 Madrid, Spain.
Cancers (Basel). 2025 Mar 28;17(7):1137. doi: 10.3390/cancers17071137.
BACKGROUND/OBJECTIVES: Brentuximab vedotin (BV) has been shown to be effective in the treatment of classical Hodgkin's lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and CD30-positive cutaneous T-cell lymphoma (CTCL). This study aimed to evaluate the effectiveness and safety of BV retreatment in patients with relapsed/refractory cHL, sALCL, and CD30-positive CTCL.
This multicenter, non-interventional, retrospective medical chart review study analyzed medical records from 43 patients retreated with BV in Spain. Patients were included if they had relapsed or refractory cHL, sALCL, or CD30-positive CTCL and were previously treated with BV. Demographic characteristics, disease stage, response to treatment, survival outcomes, and adverse events were analyzed.
The study population included 16 patients with cHL, 13 with sALCL, and 14 with CTCL. The majority were male (58.1%) with a mean age of 46.2 years and baseline ECOG scores of 0-1. Among cHL and sALCL patients, disease stage, according to the Ann Arbor classification, ranged from I to IVB, while in CTCL, EORTC clinical stages ranged from IA to IVB. The overall response rate to BV retreatment was 76.7%, with the highest response observed in sALCL (92.3%). Complete remission was achieved in 60.5% of patients. Median progression-free survival was 25.4 months, and overall survival reached 50 months. Treatment failure occurred in 37.2% of patients. BV was generally well tolerated, with peripheral neuropathy being the most frequently reported adverse event.
The BELIEVE study is the largest study to date demonstrating that retreatment with BV is an effective and well-tolerated option for patients with relapsed or refractory CD30-positive malignancies.
背景/目的：已证明维布妥昔单抗（BV）在治疗经典型霍奇金淋巴瘤（cHL）、系统性间变性大细胞淋巴瘤（sALCL）和CD30阳性皮肤T细胞淋巴瘤（CTCL）方面有效。本研究旨在评估BV再治疗对复发/难治性cHL、sALCL和CD30阳性CTCL患者的有效性和安全性。
这项多中心、非干预性、回顾性病历审查研究分析了西班牙43例接受BV再治疗患者的病历。纳入标准为复发或难治性cHL、sALCL或CD30阳性CTCL且曾接受BV治疗的患者。分析了人口统计学特征、疾病分期、治疗反应、生存结果和不良事件。
研究人群包括16例cHL患者、13例sALCL患者和14例CTCL患者。大多数为男性（58.1%），平均年龄46.2岁，基线ECOG评分为0 - 1。在cHL和sALCL患者中，根据Ann Arbor分类，疾病分期为I至IVB，而在CTCL中，EORTC临床分期为IA至IVB。BV再治疗的总体缓解率为76.7%，其中sALCL的缓解率最高（92.3%）。60.5%的患者实现完全缓解。中位无进展生存期为25.4个月，总生存期达50个月。37.2%的患者出现治疗失败。BV总体耐受性良好，周围神经病变是最常报告的不良事件。
BELIEVE研究是迄今为止规模最大的研究，证明BV再治疗是复发或难治性CD30阳性恶性肿瘤患者的一种有效且耐受性良好的选择。
